安非他明己二酸 | 64770-51-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 安非他明己二酸
• 英文名称: Amphetamine adipate
• 英文别名: hexanedioic acid;1-phenylpropan-2-amine
• CAS: 64770-51-0
• 化学式: C15H23NO4
• 分子量: 281.35
• InChiKey: OFCJKOOVFDGTLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.29
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Combinatorial analysis and repair
  申请人：Pedersen Henrik

  公开号：US10722562B2

  公开（公告）日：2020-07-28

  A method for the repair of a unit, by specific diagnosis of the undesired state, and its appropriate repair, using said specific diagnosis as a means to repair in an appropriate way said unit. The diagnosis and repair processes may involve chemical, physical, or mechanical means. The units being diagnosed and repaired include live matter (e.g. human beings, animals, plants) as well as non-live matter (e.g. buildings, electronic equipment, polymer materials).

  通过对不希望出现的状态进行特定诊断，并利用所述特定诊断作为以适当方式修复所述装置的手段，对装置进行适当修复的方法。诊断和修复过程可能涉及化学、物理或机械手段。被诊断和修复的单元包括活体（如人类、动物、植物）和非活体（如建筑物、电子设备、高分子材料）。
• Engineered receptor/ligand system for delivery of therapeutic agents
  申请人：University of Florida Research Foundation, Incorporated

  公开号：US11000597B2

  公开（公告）日：2021-05-11

  Provided herein are compositions and methods related to targeted delivery of a therapeutic or diagnostic agent to a subject utilizing an engineered receptor-ligand system, such as an engineered dockerin-cohesin system. As described herein, previously-developed targeted delivery systems for delivering therapeutic and diagnostic agents to a tissue of interest have drawbacks that have not been addressed to date. For example, with respect to the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB), both of which hamper delivery of agents to the brain, others have relied on the use of endogenously expressed receptors, like the transferrin receptor, to assist the agent across the barriers.

  本文提供了与利用工程受体-配体系统（如工程 dockerin-cohesin系统）向受试者靶向递送治疗剂或诊断剂有关的组合物和方法。如本文所述，以前开发的将治疗剂和诊断剂靶向输送到相关组织的靶向输送系统存在迄今尚未解决的缺点。例如，血脑屏障（BBB）和血-脑脊液屏障（BCSFB）都会阻碍将药剂输送到大脑，因此其他药物依赖于使用内源性表达的受体（如转铁蛋白受体）来帮助药剂穿过屏障。
• TRANSDERMAL DRUG DELIVERY FORMULATION
  申请人：Nuvo Research Inc.

  公开号：EP1909772A1

  公开（公告）日：2008-04-16
• Penetration Enhancer Combinations for Transdermal Delivery
  申请人：Mitragotri Samir

  公开号：US20070269379A1

  公开（公告）日：2007-11-22

  A high throughput screening and isolation system identifies rare enhancer mixtures from a candidate pool of penetration enhancer combinations. The combinations are screened for high penetration but low irritation potential using a unique data mining method to find new potent and safe chemical penetration enhancer combinations. The members of a library of chemical penetration enhancer combinations are screened with a high throughput device to identify “hot spots”, particular combinations that show higher chemical penetration enhancement compared to neighboring compositions. The irritation potentials of the hot spot combinations are measured to identify combinations that also show low irritation potential. A active component, such as a drug, is then combined with the combination in a formulation which is tested for the ability of the drug to penetrate into or through skin. It is then assessed whether the formulation can deliver the quantity of drug required, and animal tests are conducted to confirm in vivo the ability of the chemical penetration enhancer combinations to facilitate transport of sufficient active molecules across the skin to achieve therapeutic levels of the active molecule in the animal's blood. The invention provides specific unique and rare mixtures of chemical penetration enhancers that enhance skin permeability to hydrophilic macromolecules by more than 50-fold without inducing skin irritation, such as combinations of sodium laurel ether sulfate and 1-phenyl piperazine, and combinations of N-lauryl sarcosine and Span 20/sorbitan monolaurate.
• Transdermal Drug Delivery Formulation
  申请人：Singh Jagat

  公开号：US20080319092A1

  公开（公告）日：2008-12-25

  The present invention provides a transdermal formulation for the delivery of at least one active agent. The formulation includes (i) a first compound comprising an organic sulfoxide, and (ii) a second compound selected from the group consisting of a fatty acid ester, a fatty acid, an azone-related compound and mixtures thereof.